On the basis of the hypothesis that inhibition of PTEN might modulate inflammatory immune responses in metabolic disorders exacerbated by chronic stress, we have now tested the effects of pharmacological inhibition of PTEN and restraint stress on heart and AT pathology as well as immune activity in this MetS model. The gene discussed is PTEN; the disease is metabolic disease.